Cells (Oct 2022)

Pathological Role of HDAC8: Cancer and Beyond

  • Ji Yoon Kim,
  • Hayoung Cho,
  • Jung Yoo,
  • Go Woon Kim,
  • Yu Hyun Jeon,
  • Sang Wu Lee,
  • So Hee Kwon

DOI
https://doi.org/10.3390/cells11193161
Journal volume & issue
Vol. 11, no. 19
p. 3161

Abstract

Read online

Histone deacetylase 8 (HDAC8) is a class I HDAC that catalyzes the deacetylation of histone and non-histone proteins. As one of the best-characterized isoforms, numerous studies have identified interacting partners of HDAC8 pertaining to diverse molecular mechanisms. Consequently, deregulation and overexpression of HDAC8 give rise to diseases. HDAC8 is especially involved in various aspects of cancer progression, such as cancer cell proliferation, metastasis, immune evasion, and drug resistance. HDAC8 is also associated with the development of non-cancer diseases such as Cornelia de Lange Syndrome (CdLS), infectious diseases, cardiovascular diseases, pulmonary diseases, and myopathy. Therefore, HDAC8 is an attractive therapeutic target and various HDAC8 selective inhibitors (HDAC8is) have been developed. Here, we address the pathological function of HDAC8 in cancer and other diseases, as well as illustrate several HDAC8is that have shown anti-cancer effects.

Keywords